person · Reporting owner

SASSINE ANDY

Disclosed activity across 6 companies

Tapewire entity: 76273
SEC CIK: 0001515322

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523	Director · Chief Financial Officer	August 15, 2025	August 20, 2025
Arcturus Therapeutics Ltd.ARCT · Entity 160417	Director · Chief Financial Officer	January 01, 2019	January 02, 2019
EXICURE, INC.XCUR · Entity 8068	Director	June 02, 2021	June 04, 2021
MetaVia Inc.GEMP · Entity 7947	Director	July 24, 2019	July 26, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arcturus Therapeutics Holdings Inc.

Report date August 15, 2025 · Filed August 20, 2025 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	221,764	Reported balance After 2025-08-15 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2025-08-15 · Purchase · Acquired 1,238 · Balance 221,764 F1: The purchase reported on this Form 4 was effected by the Reporting Person pursuant to the Arcturus Therapeutics Holdings Inc. 2020 Employee Stock Purchase Plan (the "ESPP"). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 15, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: The purchase reported on this Form 4 was effected by the Reporting Person pursuant to the Arcturus Therapeutics Holdings Inc. 2020 Employee Stock Purchase Plan (the "ESPP").

F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 15, 2025.

Arcturus Therapeutics Ltd.

Report date January 01, 2019 · Filed January 02, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	237,596	Reported balance Holding disclosure · report date 2019-01-01 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 237,596 F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.
STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23	Direct	Not disclosed	Reported balance Holding disclosure · report date 2019-01-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F2: Fully vested as of December 31, 2018.
STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23	Direct	Not disclosed	Reported balance Holding disclosure · report date 2019-01-01 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F3: Vesting monthly over a one year period from August 24, 2018.
STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23	Direct	Not disclosed	Reported balance Holding disclosure · report date 2019-01-01 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.
STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23	Direct	Not disclosed	Reported balance Holding disclosure · report date 2019-01-01 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F3: Vesting monthly over a one year period from August 24, 2018.
STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2028-12-31	Direct	Not disclosed	Reported balance Holding disclosure · report date 2019-01-01 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F4: Options to purchase 25,000 shares vest one year from the date of grant and the remainder vests in equal monthly installments over the three year period thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.

F2: Fully vested as of December 31, 2018.

F3: Vesting monthly over a one year period from August 24, 2018.

F4: Options to purchase 25,000 shares vest one year from the date of grant and the remainder vests in equal monthly installments over the three year period thereafter.

EXICURE, INC.

Report date June 02, 2021 · Filed June 04, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2031-06-01	Direct	50,000	Reported balance After 2021-06-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-02 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date.

MetaVia Inc.

Report date July 24, 2019 · Filed July 26, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	151,264	Reported balance After 2019-07-24 transaction · row 1 1 source row Row 1 · 2019-07-24 · Grant · Acquired 15,000 · Balance 151,264

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Emmaus Life Sciences, Inc.

Report date November 01, 2016 · Filed November 03, 2016

Section 16 reporting ended · disclosed 2016-11-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2026-09-22	Direct	20,000	Reported balance After 2016-11-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-11-01 · Grant · Acquired 20,000 · Balance 20,000 F1: The option grant was recommended by the compensation committee and approved by the board of directors of MYnd Analytics, Inc. (the "Registrant") on September 22, 2016, subject to stockholder approval of the Amended and Restated 2012 Omnibus Incentive Compensation Plan (the "Plan") under which the option was granted. The Registrant's stockholders approved the Plan on November 1, 2016.

Filing footnotes · ownership attribution and instrument terms

F1: The option grant was recommended by the compensation committee and approved by the board of directors of MYnd Analytics, Inc. (the "Registrant") on September 22, 2016, subject to stockholder approval of the Amended and Restated 2012 Omnibus Incentive Compensation Plan (the "Plan") under which the option was granted. The Registrant's stockholders approved the Plan on November 1, 2016.

ICAD INC

Report date July 17, 2025 · Filed July 17, 2025

Section 16 reporting ended · disclosed 2025-07-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-07-17 transaction · row 1 1 source row Row 1 · 2025-07-17 · Disposition to issuer · Disposed 1,198,382 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 15, 2025 (the "Merger Agreement"), by and among the Issuer, RadNet, Inc., a Delaware corporation ("RadNet"), and Trio Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of RadNet (Merger Sub"), pursuant to which, among other things, Merger Sub merged with and into the Issuer (the "Merger") on July 17, 2025 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("iCAD Stock") was automatically canceled and retired, and was converted into the right to receive 0.0677 shares (the "Exchange Ratio") of common stock of RadNet ("RadNet Stock"), and, if applicable, cash in lieu of fractional shares.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.05	Direct	Reported balance After 2025-07-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-07-17 · Disposition to issuer · Disposed 6,219 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.91	Direct	Reported balance After 2025-07-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-07-17 · Disposition to issuer · Disposed 6,517 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.70	Direct	Reported balance After 2025-07-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-07-17 · Disposition to issuer · Disposed 9,321 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.70	Direct	Reported balance After 2025-07-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-07-17 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.81	Direct	Reported balance After 2025-07-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-07-17 · Disposition to issuer · Disposed 4,002 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.20	Direct	Reported balance After 2025-07-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-07-17 · Disposition to issuer · Disposed 2,672 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00	Direct	Reported balance After 2025-07-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-07-17 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.20	Direct	Reported balance After 2025-07-17 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-07-17 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95	Direct	Reported balance After 2025-07-17 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-07-17 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.46	Direct	Reported balance After 2025-07-17 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-07-17 · Disposition to issuer · Disposed 28,774 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70	Direct	Reported balance After 2025-07-17 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-07-17 · Disposition to issuer · Disposed 12,954 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34	Direct	Reported balance After 2025-07-17 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2025-07-17 · Disposition to issuer · Disposed 34,706 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.78	Direct	Reported balance After 2025-07-17 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2025-07-17 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57	Direct	Reported balance After 2025-07-17 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2025-07-17 · Disposition to issuer · Disposed 30,265 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52	Direct	Reported balance After 2025-07-17 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2025-07-17 · Disposition to issuer · Disposed 22,259 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.49	Direct	Reported balance After 2025-07-17 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2025-07-17 · Disposition to issuer · Disposed 27,586 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.06	Direct	Reported balance After 2025-07-17 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2025-07-17 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 15, 2025 (the "Merger Agreement"), by and among the Issuer, RadNet, Inc., a Delaware corporation ("RadNet"), and Trio Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of RadNet (Merger Sub"), pursuant to which, among other things, Merger Sub merged with and into the Issuer (the "Merger") on July 17, 2025 (the "Effective Time").

F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("iCAD Stock") was automatically canceled and retired, and was converted into the right to receive 0.0677 shares (the "Exchange Ratio") of common stock of RadNet ("RadNet Stock"), and, if applicable, cash in lieu of fractional shares.

F3: At the Effective Time, each option to purchase shares of iCAD Stock (whether or not vested or exercisable) outstanding and unexercised immediately prior to the Effective Time with an exercise price of less than $7.20 (each, an "Eligible iCAD Option") was assumed by RadNet and converted into an option (i) to purchase a number of shares of RadNet Stock equal to the product of (1) the number of shares of iCAD Stock subject to such Eligible iCAD Option immediately prior to the Effective Time and (2) the Exchange Ratio, rounded down to the nearest whole number, and (ii) with an exercise price equal to (1) the exercise price per share of iCAD Stock of such Eligible iCAD Option immediately prior to the Effective Time, divided by (2) the Exchange Ratio, rounded up to the nearest cent. Each outstanding and unexercised iCAD option that was not an Eligible iCAD Option terminated and ceased to be outstanding as of the Effective Time without any consideration payable for such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 14, 2021 Filed Sep 15, 2021 19:22 UTC	ICAD INC ICAD · Entity 77446	SaleCommon Stock	10,000	$10.68	$106,800.00	Disclosure SEC source: 0000899243-21-036179 · doc4.xml · nonDerivative · entry 2 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,298,382 F1 · shares: Represents shares sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, which provides for the sale of 20,000 shares each month until August 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.31 to $11.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it at each separate price on September 14, 2021. Read SEC document
September 13, 2021 Filed Sep 15, 2021 19:22 UTC	ICAD INC ICAD · Entity 77446	SaleCommon Stock	10,000	$11.09	$110,900.00	Disclosure SEC source: 0000899243-21-036179 · doc4.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,308,382 F1 · shares: Represents shares sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, which provides for the sale of 20,000 shares each month until August 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.85 to $11.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it at each separate price on September 13, 2021. Read SEC document
June 02, 2021 Filed Jun 4, 2021 17:19 UTC	EXICURE, INC. XCUR · Entity 8068	GrantStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $1.71	$0.00	Disclosure SEC source: 0001209191-21-038325 · doc4.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date. Read SEC document
March 05, 2021 Filed Mar 8, 2021 18:56 UTC	EXICURE, INC. XCUR · Entity 8068	GrantStock Option (right to buy) · Derivative	100,000	$0.00 Strike: $2.06	$0.00	Disclosure SEC source: 0001209191-21-018734 · doc4.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-03-04 F1 · derivative.exercise_date: The shares subject to the option vest in 36 substantially equal monthly installments from the vesting commencement date of March 5, 2021, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
February 15, 2021 Filed Feb 17, 2021 21:41 UTC	ICAD INC ICAD · Entity 77446	GrantStock Option · Derivative	30,000	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0000899243-21-007047 · doc4.xml · derivative · entry 2 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2026-02-15 F2 · derivative.exercise_date: The shares underlying the option vest quarterly over a period of 12 months from the grant date. Read SEC document
February 15, 2021 Filed Feb 17, 2021 21:41 UTC	ICAD INC ICAD · Entity 77446	GrantCommon Stock	3,500	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-007047 · doc4.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318,382 F1 · security: Represents an award of restricted stock, which vests quarterly over a period of 12 months from the grant date. F1 · price: Represents an award of restricted stock, which vests quarterly over a period of 12 months from the grant date. Read SEC document
December 31, 2020 Filed Jan 5, 2021 17:12 UTC	ICAD INC icad · Entity 77446	GrantDirector Stock Option (right to buy) · Derivative	2,672	$0.00 Strike: $13.20	$0.00	Disclosure SEC source: 0000749660-21-000002 · primary_doc.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,672 Underlying: Common Stock · 2,672 shares Expires 2025-12-31 F1 · derivative.exercise_date: The options are exercisable commencing on the Date of Grant. Read SEC document
December 18, 2020 Filed Dec 22, 2020 19:39 UTC	Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523	GrantStock Option (right to buy) · Derivative	100,000	$0.00 Strike: $99.29	$0.00	Disclosure SEC source: 0001193805-20-001608 · e620162_4-sassine.xml · derivative · entry 2 SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-18 F2 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter. Read SEC document
September 30, 2020 Filed Oct 1, 2020 17:04 UTC	ICAD INC icad · Entity 77446	GrantDirector Stock Option (right to buy) · Derivative	4,002	$0.00 Strike: $8.81	$0.00	Disclosure SEC source: 0000749660-20-000042 · primary_doc.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,002 Underlying: Common Stock · 4,002 shares Expires 2025-09-30 F1 · derivative.exercise_date: The options are exercisable commencing on the Date of Grant. Read SEC document
September 09, 2020 Filed Sep 9, 2020 16:57 UTC	ICAD INC icad · Entity 77446	SaleCommon Stock	10,000	$9.47	$94,746.00	Disclosure SEC source: 0000749660-20-000040 · primary_doc.xml · nonDerivative · entry 2 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,314,882 F1 · shares: These shares were sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The prices reported are a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it at each separate price on September 8, 2020 and September 9, 2020. Read SEC document
September 08, 2020 Filed Sep 9, 2020 16:57 UTC	ICAD INC icad · Entity 77446	SaleCommon Stock	10,000	$9.40	$93,977.00	Disclosure SEC source: 0000749660-20-000040 · primary_doc.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,324,882 F1 · shares: These shares were sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The prices reported are a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it at each separate price on September 8, 2020 and September 9, 2020. Read SEC document
August 07, 2020 Filed Aug 10, 2020 16:28 UTC	ICAD INC icad · Entity 77446	SaleCommon Stock	10,000	$10.28	$102,821.00	Disclosure SEC source: 0000749660-20-000037 · primary_doc.xml · nonDerivative · entry 2 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,334,882 F1 · shares: These shares were sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The prices reported are a weighted wtd average price. These shares were sold in multiple transactions at prices ranging from $10.06 to $10.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it at each separate price on August 6, 2020 and August 7, 2020. Read SEC document
August 06, 2020 Filed Aug 10, 2020 16:28 UTC	ICAD INC icad · Entity 77446	SaleCommon Stock	10,000	$10.31	$103,079.00	Disclosure SEC source: 0000749660-20-000037 · primary_doc.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,344,882 F1 · shares: These shares were sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The prices reported are a weighted wtd average price. These shares were sold in multiple transactions at prices ranging from $10.06 to $10.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it at each separate price on August 6, 2020 and August 7, 2020. Read SEC document
July 14, 2020 Filed Jul 15, 2020 11:17 UTC	ICAD INC icad · Entity 77446	SaleCommon Stock	10,000	$9.48	$94,754.00	Disclosure SEC source: 0000749660-20-000035 · primary_doc.xml · nonDerivative · entry 2 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354,882 F1 · shares: These shares were sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.01 to $9.88 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it at each separate price on July 14, 2020. Read SEC document
July 13, 2020 Filed Jul 15, 2020 11:17 UTC	ICAD INC icad · Entity 77446	SaleCommon Stock	10,000	$9.53	$95,300.00	Disclosure SEC source: 0000749660-20-000035 · primary_doc.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,364,882 F1 · shares: These shares were sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
June 30, 2020 Filed Jul 1, 2020 14:16 UTC	ICAD INC icad · Entity 77446	GrantDirector Stock Option (right to buy) · Derivative	3,542	$0.00 Strike: $9.99	$0.00	Disclosure SEC source: 0000749660-20-000032 · primary_doc.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,542 Underlying: Common Stock · 3,542 shares Expires 2025-06-30 F1 · derivative.exercise_date: The options are exercisable commencing on the Date of Grant. Read SEC document
June 10, 2020 Filed Jun 10, 2020 21:59 UTC	Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523	PurchaseCommon Stock	5,000	$29.74	$148,700.00	Disclosure SEC source: 0000899243-20-016049 · doc4.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,245 Read SEC document
April 01, 2020 Filed Apr 2, 2020 17:05 UTC	ICAD INC icad · Entity 77446	GrantDirector Stock Option (right to buy) · Derivative	5,448	$0.00 Strike: $6.63	$0.00	Disclosure SEC source: 0000749660-20-000024 · primary_doc.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,448 Underlying: Common Stock · 5,448 shares Expires 2025-04-01 F1 · derivative.exercise_date: The options are exercisable commencing on the Date of Grant. Read SEC document
March 20, 2020 Filed Mar 24, 2020 16:46 UTC	ICAD INC icad · Entity 77446	ConversionConvertible Debenture · Derivative	40,000	$0.00 Strike: $7.51	$0.00	Disclosure SEC source: 0000749660-20-000015 · primary_doc.xml · derivative · entry 2 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,015 shares Expires 2021-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.underlying_shares: Represents the shares of common stock issuable as make whole conversion shares by dividing the make whole amount under the convertible debenture by the make whole conversion rate as of March 19, 2020, less the shares previously issued as pre-make whole conversion shares on February 20, 2020 at the make whole conversion rate of $12.08 per shares. Read SEC document
March 20, 2020 Filed Mar 24, 2020 16:46 UTC	ICAD INC icad · Entity 77446	ConversionCommon Stock	2,015	$7.51	$15,132.65	Disclosure SEC source: 0000749660-20-000015 · primary_doc.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the shares of common stock issuable as make whole conversion shares by dividing the make whole amount under the convertible debenture by the make whole conversion rate as of March 19, 2020, less the shares previously issued as pre-make whole conversion shares on February 20, 2020 at the make whole conversion rate of $12.08 per shares. Read SEC document
February 21, 2020 Filed Feb 25, 2020 16:58 UTC	ICAD INC icad · Entity 77446	ConversionConvertible Debenture · Derivative	40,000	$0.00 Strike: $12.08	$0.00	Disclosure SEC source: 0000749660-20-000009 · primary_doc.xml · derivative · entry 4 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,312 shares Expires 2021-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.underlying_shares: Represents the shares of common stock issuable as pre-make whole conversion share by dividing the make whole amount under the convertible debenture by the make whole conversion rate as of February 20, 2020 of $12.08 per share. Read SEC document
February 21, 2020 Filed Feb 25, 2020 16:58 UTC	ICAD INC icad · Entity 77446	ConversionConvertible Debenture · Derivative	400,000	$0.00 Strike: $4.00	$0.00	Disclosure SEC source: 0000749660-20-000009 · primary_doc.xml · derivative · entry 3 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2021-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.underlying_shares: Represents the shares of common stock issuable upon forced conversion of the outstanding principal amount of the convertible debenture by dividing the outstanding principal amount of the convertible debenture by the conversion rate of $4.00 per share. Read SEC document
February 21, 2020 Filed Feb 25, 2020 16:58 UTC	ICAD INC icad · Entity 77446	ConversionCommon Stock	3,312	$12.08	$40,008.96	Disclosure SEC source: 0000749660-20-000009 · primary_doc.xml · nonDerivative · entry 2 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,372,867 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the shares of common stock issuable as pre-make whole conversion share by dividing the make whole amount under the convertible debenture by the make whole conversion rate as of February 20, 2020 of $12.08 per share. Read SEC document
February 21, 2020 Filed Feb 25, 2020 16:58 UTC	ICAD INC icad · Entity 77446	ConversionCommon Stock	100,000	$4.00	$400,000.00	Disclosure SEC source: 0000749660-20-000009 · primary_doc.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,369,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the shares of common stock issuable upon forced conversion of the outstanding principal amount of the convertible debenture by dividing the outstanding principal amount of the convertible debenture by the conversion rate of $4.00 per share. Read SEC document
February 18, 2020 Filed Feb 20, 2020 20:02 UTC	Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523	GrantStock Option (right to buy) · Derivative	80,000	$0.00 Strike: $14.12	$0.00	Disclosure SEC source: 0000899243-20-005383 · doc4.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-02-18 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter. Read SEC document
January 01, 2020 Filed Jan 3, 2020 17:26 UTC	ICAD INC icad · Entity 77446	GrantDirector Stock Option (right to buy) · Derivative	30,000	$0.00 Strike: $7.77	$0.00	Disclosure SEC source: 0000749660-20-000003 · primary_doc.xml · derivative · entry 2 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2025-01-01 F2 · derivative.exercise_date: The options are exercisable in four equal quarterly installments through the first anniversary of the Date of Grant. Read SEC document
December 31, 2019 Filed Jan 3, 2020 17:26 UTC	ICAD INC icad · Entity 77446	GrantDirector Stock Option (right to buy) · Derivative	5,577	$0.00 Strike: $7.77	$0.00	Disclosure SEC source: 0000749660-20-000003 · primary_doc.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,577 Underlying: Common Stock · 5,577 shares Expires 2024-12-31 F1 · derivative.exercise_date: The options are exercisable commencing on the Date of Grant. Read SEC document
December 05, 2019 Filed Dec 9, 2019 21:45 UTC	Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523	PurchaseCommon Stock	5,649	$9.73	$54,964.77	Disclosure SEC source: 0000899243-19-028803 · doc4.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,245 F1 · price: The price reported in Column 4 is an average price. These shares were acquired in multiple transactions at prices ranging from $9.70 to $9.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price on the Transaction Date. Read SEC document
December 03, 2019 Filed Dec 5, 2019 21:39 UTC	Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523	PurchaseCommon Stock	10,000	$10.00	$100,000.00	Disclosure SEC source: 0000899243-19-028631 · doc4.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,596 Read SEC document
September 30, 2019 Filed Oct 2, 2019 16:45 UTC	ICAD INC icad · Entity 77446	GrantDirector Stock Option (right to buy) · Derivative	5,458	$0.00 Strike: $6.85	$0.00	Disclosure SEC source: 0000749660-19-000020 · primary_doc.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,458 Underlying: Common Stock · 5,458 shares Expires 2024-09-30 F1 · derivative.exercise_date: The options are exercisable commencing on the Date of Grant. Read SEC document
August 23, 2019 Filed Aug 26, 2019 07:00 UTC	Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523	PurchaseCommon Stock	10,000	$10.90	$109,000.00	Disclosure SEC source: 0000899243-19-022418 · doc4.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,596 F1 · price: The price reported in Column 4 is a weighted average price. 1,500 shares were purchased at a price of $10.91 per share, 5,000 shares were purchased at a price of $10.94 per share and 3,500 shares were purchased at a price of $10.85 per share. Read SEC document
July 24, 2019 Filed Jul 26, 2019 16:38 UTC	MetaVia Inc. GEMP · Entity 7947	GrantCommon Stock	15,000	$0.00	$0.00	Disclosure SEC source: 0001596771-19-000085 · primary_doc.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,264 Read SEC document
June 28, 2019 Filed Jul 2, 2019 14:06 UTC	ICAD INC icad · Entity 77446	GrantDirector Stock Option (right to buy) · Derivative	5,512	$0.00 Strike: $6.37	$0.00	Disclosure SEC source: 0000749660-19-000016 · primary_doc.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,512 Underlying: Common Stock · 5,512 shares Expires 2024-06-28 F1 · derivative.exercise_date: The options are exercisable commencing on the Date of Grant. Read SEC document
March 29, 2019 Filed Apr 1, 2019 15:40 UTC	ICAD INC icad · Entity 77446	GrantDirector Stock Option (right to buy) · Derivative	6,584	$0.00 Strike: $5.17	$0.00	Disclosure SEC source: 0000749660-19-000011 · primary_doc.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,584 Underlying: Common Stock · 6,584 shares Expires 2024-03-29 F1 · derivative.exercise_date: The options are exercisable commencing on the Date of Grant. Read SEC document
January 01, 2019 Filed Jan 2, 2019 17:47 UTC	ICAD INC icad · Entity 77446	GrantDirector Stock Options (right to buy) · Derivative	20,000	$0.00 Strike: $3.70	$0.00	Disclosure SEC source: 0000749660-19-000004 · primary_doc.xml · derivative · entry 2 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2024-01-01 F2 · derivative.exercise_date: The options are exercisable quarterly over a one year period. Read SEC document
December 31, 2018 Filed Jan 2, 2019 17:47 UTC	ICAD INC icad · Entity 77446	GrantDirector Stock Option (right to buy) · Derivative	9,321	$0.00 Strike: $3.70	$0.00	Disclosure SEC source: 0000749660-19-000004 · primary_doc.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,321 Underlying: Common Stock · 9,321 shares Expires 2023-12-31 F1 · derivative.exercise_date: The options are exercisable commencing on the Date of Grant. Read SEC document
December 31, 2018 Filed Mar 9, 2023 21:32 UTC	ICAD INC ICAD · Entity 77446	Disposition to issuerDirector Stock Option (right to buy) · Derivative	9,321	Not disclosed Strike: $3.70	Not disclosed	Disclosure SEC source: 0000899243-23-007798 · doc4.xml · derivative · entry 5 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,321 shares Expires 2023-12-31 F3 · kind: The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 31, 2018 and is fully vested as of the date hereof. F4 · kind: On March 7, 2023, the Board of Directors of the Issuer agreed to a modification of the exercise period for certain outstanding stock options granted to the Director in 2018 that would otherwise expire in November 2023 such that they now have an aggregate exercise period of ten years. No other modification was made to the option. F3 · price: The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 31, 2018 and is fully vested as of the date hereof. F4 · price: On March 7, 2023, the Board of Directors of the Issuer agreed to a modification of the exercise period for certain outstanding stock options granted to the Director in 2018 that would otherwise expire in November 2023 such that they now have an aggregate exercise period of ten years. No other modification was made to the option. F3 · derivative.exercise_date: The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 31, 2018 and is fully vested as of the date hereof. F4 · derivative.exercise_date: On March 7, 2023, the Board of Directors of the Issuer agreed to a modification of the exercise period for certain outstanding stock options granted to the Director in 2018 that would otherwise expire in November 2023 such that they now have an aggregate exercise period of ten years. No other modification was made to the option. Read SEC document
December 21, 2018 Filed Dec 27, 2018 16:16 UTC	ICAD INC ICAD · Entity 77446	GrantConvertible Debenture · Derivative	100,000	$4.00 Strike: $4.00	$400,000.00	Disclosure SEC source: 0000899243-18-031821 · doc4.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2021-12-21 F1 · shares: The number of Convertible Debentures purchased was derived by diving the amount of the reporting person's investment by the conversion price of the Convertible Debentures. F2 · derivative.exercise_date: The Convertible Debentures bear interest of 5% per annum, payable semi-annually on December 21 and June 21. Read SEC document
September 28, 2018 Filed Oct 2, 2018 16:55 UTC	ICAD INC icad · Entity 77446	GrantDirector Stock Option (right to buy) · Derivative	6,517	$0.00 Strike: $2.91	$0.00	Disclosure SEC source: 0000749660-18-000040 · primary_doc.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,517 Underlying: Common Stock · 6,517 shares Expires 2023-09-28 F1 · derivative.exercise_date: The options are exercisable commencing on the Date of Grant. Read SEC document
September 28, 2018 Filed Mar 9, 2023 21:32 UTC	ICAD INC ICAD · Entity 77446	Disposition to issuerDirector Stock Option (right to buy) · Derivative	6,517	Not disclosed Strike: $2.91	Not disclosed	Disclosure SEC source: 0000899243-23-007798 · doc4.xml · derivative · entry 3 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,517 shares Expires 2023-09-28 F2 · kind: The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on September 28, 2018 and is fully vested as of the date hereof. F4 · kind: On March 7, 2023, the Board of Directors of the Issuer agreed to a modification of the exercise period for certain outstanding stock options granted to the Director in 2018 that would otherwise expire in November 2023 such that they now have an aggregate exercise period of ten years. No other modification was made to the option. F2 · price: The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on September 28, 2018 and is fully vested as of the date hereof. F4 · price: On March 7, 2023, the Board of Directors of the Issuer agreed to a modification of the exercise period for certain outstanding stock options granted to the Director in 2018 that would otherwise expire in November 2023 such that they now have an aggregate exercise period of ten years. No other modification was made to the option. F2 · derivative.exercise_date: The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on September 28, 2018 and is fully vested as of the date hereof. F4 · derivative.exercise_date: On March 7, 2023, the Board of Directors of the Issuer agreed to a modification of the exercise period for certain outstanding stock options granted to the Director in 2018 that would otherwise expire in November 2023 such that they now have an aggregate exercise period of ten years. No other modification was made to the option. Read SEC document
June 29, 2018 Filed Jul 2, 2018 09:37 UTC	ICAD INC icad · Entity 77446	GrantDirector Stock Option (right to buy) · Derivative	6,219	$0.00 Strike: $3.05	$0.00	Disclosure SEC source: 0000749660-18-000037 · primary_doc.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,219 Underlying: Common Stock · 6,219 shares Expires 2023-06-29 F1 · derivative.exercise_date: The options are exercisable commencing on the Date of Grant. Read SEC document
June 29, 2018 Filed Mar 9, 2023 21:32 UTC	ICAD INC ICAD · Entity 77446	Disposition to issuerDirector Stock Option (right to buy) · Derivative	6,219	Not disclosed Strike: $3.05	Not disclosed	Disclosure SEC source: 0000899243-23-007798 · doc4.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,219 shares Expires 2023-06-29 F1 · kind: The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 29, 2018 and is fully vested as of the date hereof. F4 · kind: On March 7, 2023, the Board of Directors of the Issuer agreed to a modification of the exercise period for certain outstanding stock options granted to the Director in 2018 that would otherwise expire in November 2023 such that they now have an aggregate exercise period of ten years. No other modification was made to the option. F1 · price: The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 29, 2018 and is fully vested as of the date hereof. F4 · price: On March 7, 2023, the Board of Directors of the Issuer agreed to a modification of the exercise period for certain outstanding stock options granted to the Director in 2018 that would otherwise expire in November 2023 such that they now have an aggregate exercise period of ten years. No other modification was made to the option. F1 · derivative.exercise_date: The two reported transactions involved an amendment to an outstanding option, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 29, 2018 and is fully vested as of the date hereof. F4 · derivative.exercise_date: On March 7, 2023, the Board of Directors of the Issuer agreed to a modification of the exercise period for certain outstanding stock options granted to the Director in 2018 that would otherwise expire in November 2023 such that they now have an aggregate exercise period of ten years. No other modification was made to the option. Read SEC document
March 30, 2018 Filed Apr 3, 2018 14:54 UTC	ICAD INC icad · Entity 77446	GrantCommon Stock	2,841	$3.08	$8,750.28	Disclosure SEC source: 0000749660-18-000029 · primary_doc.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,269,555 F1 · security: RSA with Immediate vesting schedule. Read SEC document
February 14, 2018 Filed Feb 16, 2018 15:29 UTC	ICAD INC icad · Entity 77446	GrantCommon Stock	4,000	$0.00	$0.00	Disclosure SEC source: 0000749660-18-000016 · primary_doc.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,266,714 F1 · security: RSA with 1 year vesting. Read SEC document
January 29, 2018 Filed Jan 30, 2018 17:12 UTC	MetaVia Inc. GEMP · Entity 7947	GrantStock Option (right to buy) · Derivative	10,800	$0.00 Strike: $10.44	$0.00	Disclosure SEC source: 0001596771-18-000017 · primary_doc.xml · derivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2028-01-28 F1 · derivative.exercise_date: The option vests in a series of 12 successive equal monthly installments on the last day of each month, commencing on the grant date. Read SEC document
December 29, 2017 Filed Jan 3, 2018 13:55 UTC	ICAD INC icad · Entity 77446	GrantCommon Stock (1)	2,544	$3.44	$8,751.36	Disclosure SEC source: 0000749660-18-000003 · primary_doc.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,262,714 F1 · security: 1. RSA with Immediate vesting schedule. Read SEC document
September 29, 2017 Filed Oct 4, 2017 17:48 UTC	ICAD INC icad · Entity 77446	GrantCommon Stock	1,980	$4.42	$8,751.60	Disclosure SEC source: 0000749660-17-000022 · primary_doc.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260,170 F1 · security: RSA with Immediate vesting schedule. Read SEC document
June 30, 2017 Filed Jul 5, 2017 18:42 UTC	ICAD INC icad · Entity 77446	GrantCommon Stock	2,088	$4.19	$8,748.72	Disclosure SEC source: 0000749660-17-000011 · primary_doc.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,258,190 F1 · security: RSA with Immediate vesting schedule. Read SEC document
March 31, 2017 Filed Apr 4, 2017 15:58 UTC	ICAD INC ICAD · Entity 77446	GrantCommon Stock	1,819	$4.81	$8,749.39	Disclosure SEC source: 0001593968-17-000569 · primary_01.xml · nonDerivative · entry 1 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,256,102 F1 · security: RSA with Immediate vesting schedule Read SEC document
March 10, 2017 Filed Mar 14, 2017 18:07 UTC	MetaVia Inc. GEMP · Entity 7947	PurchaseWarrant to Purchase Common Stock · Derivative	15,840	$9.47 Strike: $10.40	$150,004.80	Disclosure SEC source: 0001596771-17-000023 · primary_doc.xml · derivative · entry 2 SASSINE ANDY · CIK 0001515322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,840 Underlying: Common Stock · 15,840 shares Expires 2022-03-15 F1 · shares: The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017. F1 · price: The shares of common stock and warrants were purchased as part of a private placement pursuant to a Securities Purchase Agreement whereby the Issuer sold units consisting of one share of the Issuer's common stock and a warrant to purchase 0.75 shares of the Issuer's common stock at a per unit price of $9.47. The private placement is expected to close on March 15, 2017. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.